Literature DB >> 19020542

BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold.

J Dierov1, P V Sanchez, B A Burke, H Padilla-Nash, M E Putt, T Ried, M Carroll.   

Abstract

Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in chromosomes and whether the phenotype is found in primary chronic myelogeneous leukemia (CML) cells. We have addressed both these issues. BCR/ABL-expressing cell lines show an increase in DNA breaks after treatment with etoposide as compared to control cells. However, although BCR/ABL-expressing cell lines have an equivalent cell survival, they have an increase in chromosomal translocations after DNA repair as compared to control cells. This demonstrates that BCR/ABL expression decreases the fidelity of DNA repair. To see whether this is true in primary CML samples, normal CD34+ progenitor cells and CML progenitor cells were treated with etoposide. CML progenitor cells have equivalent survival but have an increase in DNA double-strand breaks (DSBs). Spectral karyotyping demonstrates new chromosomal translocations in CML cells, but not normal progenitor cells, consistent with error-prone DNA repair. Taken together, these data demonstrate that BCR/ABL enhances the accumulation of DSBs and alters the apoptotic threshold in CML leading to error-prone DNA repair.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020542      PMCID: PMC3650088          DOI: 10.1038/leu.2008.308

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.

Authors:  M Sattler; S Verma; G Shrikhande; C H Byrne; Y B Pride; T Winkler; E A Greenfield; R Salgia; J D Griffin
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

2.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

3.  ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.

Authors:  Margaret Nieborowska-Skorska; Tomasz Stoklosa; Mandrita Datta; Agnieszka Czechowska; Lori Rink; Artur Slupianek; Mateusz Koptyra; Ilona Seferynska; Konrad Krszyna; Janusz Blasiak; Tomasz Skorski
Journal:  Cell Cycle       Date:  2006-05-01       Impact factor: 4.534

4.  Jumping translocations are common in solid tumor cell lines and result in recurrent fusions of whole chromosome arms.

Authors:  H M Padilla-Nash; K Heselmeyer-Haddad; D Wangsa; H Zhang; B M Ghadimi; M Macville; M Augustus; E Schröck; E Hilgenfeld; T Ried
Journal:  Genes Chromosomes Cancer       Date:  2001-04       Impact factor: 5.006

5.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

Authors:  E Deutsch; A Dugray; B AbdulKarim; E Marangoni; L Maggiorella; S Vaganay; R M'Kacher; S D Rasy; F Eschwege; W Vainchenker; A G Turhan; J Bourhis
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.

Authors:  M Giehl; A Fabarius; O Frank; A Hochhaus; M Hafner; R Hehlmann; W Seifarth
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

7.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

8.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.

Authors:  M Giehl; A Fabarius; O Frank; P Erben; C Zheng; M Hafner; A Hochhaus; R Hehlmann; W Seifarth
Journal:  Leukemia       Date:  2007-06-28       Impact factor: 11.528

10.  The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.

Authors:  Michael W N Deininger; Jorge Cortes; Ron Paquette; Byung Park; Andreas Hochhaus; Michele Baccarani; Richard Stone; Thomas Fischer; Hagop Kantarjian; Dietger Niederwieser; Carlo Gambacorti-Passerini; Charlene So; Insa Gathmann; John M Goldman; Douglas Smith; Brian J Druker; François Guilhot
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

View more
  18 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.

Authors:  Leah C Young; Kathleen M Bone; Peng Wang; Fang Wu; Benjamin A Adam; Samar Hegazy; Pascal Gelebart; Jelena Holovati; Liang Li; Susan E Andrew; Raymond Lai
Journal:  Am J Pathol       Date:  2011-05-24       Impact factor: 4.307

Review 3.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

Review 4.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

5.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 6.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

7.  Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining.

Authors:  Sujata Chakraborty; Jeremy M Stark; Can-Lan Sun; Hardik Modi; WenYong Chen; Timothy R O'Connor; Stephen J Forman; Smita Bhatia; Ravi Bhatia
Journal:  Blood       Date:  2012-04-04       Impact factor: 22.113

Review 8.  Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

9.  Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Authors:  Y Dong; F Liu; C Wu; S Li; X Zhao; P Zhang; J Jiao; X Yu; Y Ji; M Zhang
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

10.  Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia.

Authors:  Elisabeth P Nacheva; Diana Brazma; Anna Virgili; Julie Howard-Reeves; Anastasios Chanalaris; Katya Gancheva; Margarita Apostolova; Mikel Valgañon; Helen Mazzullo; Colin Grace
Journal:  BMC Genomics       Date:  2010-01-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.